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Abstract Transforming growth factor-beta (TGF-b) sig-
naling plays an important role in the fetal development of
cardiovascular organs and in the repair mechanisms of the
heart. Hence, inhibitors of the TGF-b signaling pathway
require a careful identification of a safe therapeutic window
and a comprehensive monitoring of the cardiovascular
system. Seventy-nine cancer patients (67 glioma and 12
solid tumor) enrolled in a first-in-human dose study and
received the TGF-b inhibitor LY2157299 monohydrate
(LY2157299) as monotherapy (n = 53) or in combination
with lomustine (n = 26). All patients were monitored
using 2D echocardiography/color and Spectral Doppler
(2D Echo with Doppler) every 2 months, monthly elec-
trocardiograms, thorax computer tomography scans every
6 months, and monthly serum brain natriuretic peptide
(BNP), troponin I, cystatin C, high-sensitivity C-reactive
protein (hs-CRP). Administration of LY2157299 was not
associated with medically relevant cardiovascular toxici-
ties, including patients treated C6 months (n = 13). There
were no increases of troponin I, BNP, or hs-CRP or
reduction in cystatin C levels, which may have been con-
sidered as signs of cardiovascular injury. Blood pressure
was generally stable during treatment. Imaging with
echocardiography/Doppler showed an increase in mitral
and tricuspid valve regurgitation by two grades of severity
in only one patient with no concurrent clinical symptoms of
cardiovascular injury. Overall, this comprehensive cardio-
vascular monitoring for the TGF-b inhibitor LY2157299
did not detect medically relevant cardiac toxicity and hence
supports the evaluation of LY2157299 in future clinical
trials.
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Introduction
Transforming growth factor-beta (TGF-b) signaling plays
an important role in the development of cardiovascular
organs and is also a key regulator of cardiovascular
remodeling after injury [1, 2]. Its important role in onto-
genesis of the heart was identified by knocking out TGF-b
signaling proteins [3]. TGF-b ligands (TGF-b1, TGF-b2,
and TGF-b3) regulate diverse biological functions [4]. All
three ligands can bind to a specific receptor by first
engaging the TGF-b receptor type I (TGF-bRI or ALK5),
which then heterodimerizes with the TGF-bRII. This het-
erodimer complex phosphorylates the intracellular proteins
SMAD2 and SMAD3, which initiate an activation cascade
to induce several nuclear transduction proteins. By
knocking out either the ligands or the SMAD proteins, the
development of the heart can be blunted and can lead to
intrauterine death [5].
In cardiovascular disease, TGF-b signaling has been
associated with remodeling of the heart after myocardial
infarction and its overexpression has been associated with
heart failure [6]. Preclinical models have shown that
blocking TGF-b signaling with pharmacological agents can
prevent injury-induced cardiomyopathies and their associ-
ated pathologies [7]. In vessels, TGF-b signaling regulates
inflammatory responses of the endothelium and smooth
muscle to injury [8]. Shear/stress stimuli in the vessels are
one of the key inducers of TGF-b signaling [9]. This acti-
vation of TGF-b signaling can prevent aneurysm formation,
but is present in aneurysms despite a loss of function in the
TGF-b signaling pathway [10]. Such a condition is
observed in patients with Loeys–Dietz Syndrome (LDS), a
subset of Marfan Syndrome, where patients present with
aortic dilatation and thoracic aneurysms [11]. In such
patients and also in animal models mimicking the condition
of LDS patients, TGF-b signaling is induced, despite the
genetic evidence in loss of function. Toxicology studies
with TGF-b inhibitors that block TGF-b RI/ALK5 have
reported toxicities that share the cardiovascular findings in
LDS patients [12]. Such findings included structural chan-
ges of the heart valve and aneurysms of the ascending aorta
and aortic arch. These observations have discouraged the
clinical development of small molecule inhibitors.
LY2157299 monohydrate (LY2157299) is a TGF-bRI
kinase inhibitor that interrupts the receptor-mediated sig-
naling cascade. Hence, it was critical to develop a thera-
peutic window for the safe administration of LY2157299
during a first-in-human dose (FHD) study [13, 14]. During
the FHD study, the administration of LY2157299 was
accompanied with a comprehensive and prospective cardiac
safety monitoring. Cardiac safety evaluations including
echocardiography/Doppler, plasma markers of cardiac
function, electrophysiological evaluations, and radio-
graphic imaging to assess the ascending aorta and aortic
arch for aneurysm formation were used.
The results of this FHD study of LY2157299 are
described herein. Overall, the selected dose range of
LY2157299 was safe, and no significant cardiac toxicities
were observed. This monitoring approach is currently
being extended to all other ongoing trials with LY2157299.
Methods
Patients
As previously described [13], patients who had a histologic
or cytologic diagnosis of cancer for which no proven
effective therapy existed were included in the first two
cohorts. Starting with cohort 3, only patients with relapsed
and progressive glioblastoma were eligible for this study.
All patients had to have disease that was measurable or
non-measurable as defined by the Response Evaluation
Criteria in Solid Tumors (RECIST) and for patients starting
on cohort 3 onward as defined by Macdonald criteria [15].
All patients had to have performance status of B2 on the
Eastern Cooperative Oncology Group (ECOG) scale.
Patients were required to have adequate hematologic,
hepatic, and renal function, and discontinued all previous
therapies for cancer at least 4 weeks prior to the study
enrollment. Exclusion criteria included medically uncon-
trolled cardiovascular illness and medically significant
electrocardiogram (ECG) anomalies. Patients who had
major abnormalities documented by echocardiography/
Doppler, such as moderate or severe heart valve function
defect and/or left ventricular ejection fraction (LVEF) of
B50 %, were excluded from the study. Patients with tri-
cuspid (trace or mild), pulmonary, mitral (trace or mild), or
aortic (trace or mild) regurgitation by Doppler techniques
were allowed to enter the study.
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Study Design
The study was conducted according to the principles of
good clinical practice, applicable laws and regulations, and
the Declaration of Helsinki. Each institution’s review board
approved the study and all patients signed an informed
consent document before study participation.
LY2157299 was evaluated in a multicenter, open-label,
non-randomized, dose escalation First-in-Human Phase 1
study (Fig. 1). There were three parts in the study: Part A
was a dose escalation and enrolled patients with advanced
or metastatic cancer and then only glioblastoma patients for
the remainder of the study. Doses were escalated to a
predetermined top dose of 300 mg/day [13]. Each cohort
enrolled at least 3 patients and the number of patients per
cohort was adjusted based on the pharmacokinetic (PK)
profile and variability. In Part B, LY2157299 was com-
bined with lomustine at two doses, 160 and 300 mg/day.
Part C was designed as a relative bioavailability (RBA)
study; all patients remained on study treatment after the
RBA phase was completed and were then dosed with
300 mg/day LY2157299 monotherapy.
Treatment
LY2157299 was given orally at doses of 20, 40, 80, 120,
and 150 mg twice daily as a tablet in the morning and
evening. Patients in the first two cohorts received
LY2157299 daily as part of a 28-day cycle. Starting with
cohort 3, all patients received LY2157299 on Day 1–14 of
each 28-day cycle. No dose adjustments or reductions were
allowed.
Safety Assessments
Safety was evaluated in patients who received at least one
dose of LY2157299. Safety assessment was based on the
summaries of adverse events (AEs) including severity (as
defined by Common Terminology Criteria for Adverse
Events version 3.0 (CTCAE, v3.0) and possible relation-
ship to study drug, dose-limiting toxicities (DLTs) and
laboratory changes at each dose level. Standard laboratory
tests included chemistry, hematology, and urinalysis pan-
els. Safety was also analyzed by ECG using a standardized
assessment [16], echocardiography/Doppler [17], and
additional laboratory tests specifically linked to cardiac
toxicity, such as brain natriuretic peptide (BNP), troponin I,
high-sensitivity C-reactive protein (hs-CRP), and cystatin
C [18] (Figs. 1, 2). Besides the assessment of acute DLT
detailed below, serum monitoring for cardiotoxicity was
carried out beyond Cycle 1. Assessments were performed
at the end of every other cycle starting at Cycle 2, except
for cystatin C and hs-CRP which were taken at the end of
every cycle, until study treatment discontinuation.
Part B
Combination with lomustine
Cohort 1 BID - daily
Cohort 2 BID - daily
Cohort 3 BID intermittent
Cohort 5 BID intermittent
Cohort 4 BID intermittent
160 mg/day (80 mg BID) 
intermittent
300 mg/day (150 mg 
BID) intermittent
Part C
Monotherapy
relative bioavailability (RBA) 
150 mg QD in RBA 
Followed by 
300 mg (150 mg BID)
intermittent
Abbreviations:  BID, twice daily; QD, once per day
Part A
Monotherapy
Pre-studyExamination
(days)
Cycle 1
(days)
Cycle 2 - onward
(days)
14 7 1 12±2 26±2 1 12±2 26±2
Vital signs
(blood pressure and heart rate) X X X X X
Echocardiography/Doppler
(after cycle 2: every 2 cycles) XXX
CT scan of the aorta
(after cycle 3: every 2 cycles) XXX
ECG XXXXX
Troponin I + BNP XXX
hs-CRP XXX
Cystatin C X X X X X
Fig. 1 Study design of the first-
in-human dose study with
LY2157299 and timing of the
cardiovascular assessments
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Computer tomography (CT) scans or magnetic resonance
images (MRI) of the thoracic aorta specifically assessing
potential aneurysms of the ascending aorta and aortic arch
were performed based on institutional imaging procedures
[19]. Any clinically significant abnormal results were
recorded as AEs. If there were clinically significant cardiac
findings at discontinuation, echocardiography/Doppler and
ECGs were to be repeated every 2 months for 6 months. In
the event of no cardiac findings at study treatment dis-
continuation, one more echocardiography and ECG were
planned after 2 months, unless the patient had started
another treatment.
2D Echocardiography/Color Spectral Doppler
Echocardiography/Doppler were performed according to a
standard protocol and interpreted as per recommendations
of echocardiography societies [17]. All images were sub-
mitted to a central echocardiologist who reviewed all
images based on pre-specified variables (Table 1). During
the study, an echocardiography alert process was imple-
mented in order to ensure close monitoring of every
patient, and reconciliation was pre-specified between local
and central echocardiography review to ensure consistent
grading of abnormality (Fig. 3).
DLT Assessment
Dose escalation to the second cohort proceeded after three
patients completed one treatment cycle without a DLT and
after careful assessment of their PK and safety information.
Dose escalation to each subsequent dose was based on a
combination of the number of DLTs at the dose tested,
aggregate safety profile, and predicted exposure of area
under the curve. Hematologic or non-hematologic toxicity
with grade C3 was considered as a DLT in patients treated
with study medication at different dose levels according to
the National Cancer Institute and the CTCAE, v3.0. Spe-
cific DLT criteria for cardiac parameters were defined to be
an increase of one or more grades of the semi-quantitative
valvular insufficiency, left ventricular function, or right
ventricular systolic pressure (normal, mild, moderate, or
severe based on local laboratory limits). If a patient was
normal at baseline and after the first cycle increased to
mild, then a repeat echocardiography should be performed
after 14 days. If results confirmed mild grade at repeat
echocardiography, then patient was to be discontinued. If
findings were normal, then the patient continued treatment
per study protocol. In addition, an increase in left atrial or
ventricular chamber size of 2 and 1 cm, respectively, or
any evidence of damage to the heart’s large vessels from
the CT scan would also be considered a DLT. For the
serum cardiac safety markers, concentrations of BNP C 3
times the baseline value and above the upper limit of
normal (ULN) and sustained at two consecutive scheduled
blood draws, and/or concentrations of troponin I above the
ULN were also considered DLTs.
Statistical Analysis
The primary objective of this FHD study was to determine
a safe and tolerable dose for future Phase 2 studies. This
Fig. 2 Overview of the
parameters of the cardiovascular
monitoring implemented during
the first-in-human dose study
with LY2157299
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evaluation included assessment of cardiovascular toxicity
(see DLT definition above). Consistent with the traditional
DLT assessment in FHD trials of cancer patients, the study
used descriptive statistical analyses and was not powered to
determine statistically important differences between a
standard treatment and the novel treatment with
LY2157299. All summary tables and figures are given by
monotherapy and combination therapy. Demographics,
concomitant medication, and AEs were summarized using
frequencies or summary statistics as appropriate. Shift
tables to summarize maximum changes in severity after
dosing were created for overall ECG evaluation. The fre-
quency of patients experiencing increases from baseline in
QTcF were listed by category: 0–30,[30–60, and[60 ms.
For valvular regurgitation parameters, all measurements for
patients who experienced an increase in severity of at least
one grade are listed, together with the time-matched sys-
tolic blood pressure. This detail was provided in order to
help interpret the event. Line plots over time for serum
measurements and ECG parameters (together with normal
Table 1 List of cardiac
markers assessed
Per-protocol attachment
E/Em\ 15 not\10 as in
worksheet. Mitral and aortic
valve area for evidence of
stenosis should not be less than
2 and 1.5 cm/m2, respectively,
but data were not collected
BNP brain natriuretic peptide,
hs-CRP high-sensitivity
C-reactive protein, LA left
aortic, LV left ventricle, PA
pulmonary artery, RA right
aortic, RV right ventricle
Normal ranges
Serum biomarkers
Troponin I 0–0.3 lg/L
BNP 0 B age\ 45: 2.7–33 ng/L
45 B age B 54: 2.7–46.7 ng/L
55 B age\ 65: 2.7–53.2 ng/L
65 B age\ 75: 2.7–72.3 ng/L
75 B age\ 111: 2.7–176 ng/L
hs-CRP 0–3 mg/L
Cystatin C 0.53–0.95 mg/L
Echocardiography/Doppler
Continuous variables (normal range)
LV internal dimension (diastolic) B2.8 cm/m2
LA volume (end-systolic) B36 mL/m2
LA dimension (end-systolic) 1.9–4.0 cm
LV ejection fraction C50 %
LV mass B115 g/m2—male
B99 g/m2—female
PA systolic pressure B40 mmHg
Pulmonary flow velocity acceleration time C120 ms
Mitral deceleration time C160 ms and B220 ms
Mitral E/A ratio C0.75 and B1.5
E/Em \10
Systolic blood pressure Measurements in mmHg
Diastolic blood pressure Measurements in mmHg
Semi-quantitative variables (severity scale)
RA dilation Normal, mild, moderate, severe
RV dilation Normal, mild, moderate, severe
Mitral regurgitation Absent, trace, mild, moderate, severe
Aortic regurgitation Absent, trace, mild, moderate, severe
Pulmonic regurgitation Absent, present
Tricuspid regurgitation Absent, present
Wall motion Normal/abnormal
Pericardial effusion Absent, small, moderate, large
Electrocardiogram
Standard measurements
Hemodynamic measurements
Blood pressure 90/60–140/90 mmHg
Heart rate 50–100 beats/min
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limits where appropriate) and box–whisker plots for blood
pressure and left ventricular fraction are provided.
Results
A total of 79 patients were enrolled into this FHD study
from 2006 to 2012, which included a period of 2 years when
the study was placed on clinical hold awaiting new animal
toxicology data. The majority of the patients were male in
Parts A and B of the study; in Part C, there were more
females (Table 2). Most patients were younger than
60 years. In Part A, there was a higher proportion of patients
who had either a lower grade glioma or secondary glioma
compared to patients enrolled in Parts B and C. Overall,
most patients had a good performance status (ECOG 0 or 1)
at the time of their cancer progression and after failing to
respond to previous effective anticancer therapies (Table 2).
Because of the entry criteria, all patients had an unremark-
able cardiac function prior to the study entry.
Concomitant Cardiac Medications
The low number of cardiac medications suggested that
patients had relatively good cardiovascular statuses
(Table 2). The most common cardiac medication was
enalapril (6/79, 7.6 %) followed by angiotensin II receptor
blockers (5/79, 6.3 %).
Safety Measures: Treatment-Emergent Adverse Events
Of 79 patients dosed, 37 died during the study—36 due to
tumor progression and one related to pneumonia. One
patient (in Part A in the 300 mg/day cohort) was identified
as having a DLT of grade 4 thrombocytopenia. The patient
completed Cycle 2 but died due to disease progression
before he fully recovered from this event. In the entire
study, 53 patients (53/79; 67 %) experienced at least one
grade 3 or 4 adverse event, of which the events of 13 (13/
79; 16.4 %) patients were possibly related to study treat-
ment (Table 3). Two patients (2/79; 2.5 %) discontinued
from study treatment due to platelet reduction (CTCAE
v3.0 grades 2 and 4), both considered as possibly related to
study treatment.
Plasma/Serum Markers to Assess Cardiac Function
We used the markers troponin I, BNP and hs-CRP to
serially evaluate for myocardial necrosis (troponin I),
cardiac failure (BNP), or an inflammatory response (hs-
CRP) (Fig. 4). One patient on monotherapy had higher
than normal troponin I values on Days 122 and 127 post-
dose. On both occasions, the recorded value was 0.06 ng/L
(ULN = 0.05 ng/L). The patient discontinued because of
progressive disease on Day 149 and values returned to
normal on Day 156. No values were greater than the ULN
in patients treated in combination with lomustine (data not
Fig. 3 Alert and adjudication process of echocardiography/Doppler assessments between local and central echocardiography readers
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shown). For BNP, no patients on monotherapy met the pre-
specified toxicity criteria. One patient on combination
therapy had concentrations that did not meet the pre-
specified toxicity criteria and the BNP levels increased
16-fold from 3.8 ng/L at baseline to 59.0 ng/L by Day 56
(ULN age-adjusted was 53.2 ng/L). This patient discon-
tinued from study treatment on Day 64 due to tumor
progression (Fig. 4). There were some isolated instances of
increased hs-CRP, but none were sustained over time. The
isolated increases may reflect infection-related reactions,
and the lack of sustained (i.e., over several cycles)
increases of hs-CRP suggested no clinical concern of
toxicity. A reduction of cystatin C levels is thought to
predict the formation of aneurysms and was therefore
Table 2 Patient characteristics and concomitant cardiovascular medication
Characteristics Part A
N = 39
Part B
N = 26
Part C
N = 14
Age (years)
Mean (SD) 51.8 (14.88) 44.5 (10.35) 59.8 (12.74)
Median (range) 54.0 (22, 77) 43.5 (25, 61) 56.5 (34, 76)
Sex [n (%)]
Male 30 (76.9) 19 (73.1) 5 (35.7)
Female 9 (23.1) 7 (26.9) 9 (64.3)
Origin [n (%)]
Caucasian 39 (100) 24 (92.3) 14 (100)
Hispanic – 1 (3.8) –
West Asian – 1 (3.8) –
ECOG [n (%)]
0 15 (38.5) 3 (11.5) 4 (28.6)
1 19 (48.7) 17 (65.4) 8 (57.1)
2 5 (12.8) 6 (23.1) 2 (14.3)
Glioma [n (%)] n = 30a n = 26 n = 9
Low grade, Grade II–III 9 (30.0) 4 (15.4) 2 (22.2)
Secondary, Grade IV 5 (16.7) 2 (7.7) –
Primary, Grade IV 16 (53.3) 20 (76.9) 7 (77.8)
Drug class generic name Patients
(n)
Cardiovascular drugs
Alpha and beta blocking agents
Labetalol 1
Atenolol 1
Bisoprolol 2
Metoprolol tartrate 1
Angiotensin-converting enzyme
inhibitors
Enalapril 6
Lisinopril 1
Angiotensin II receptor blockers
Losartan 2
Valsartan 2
Olmesartan 1
Antiarrhythmics
Lidocaine 1
Flecainide acetate 1
ECOG Eastern Cooperative Oncology Group, SD standard deviation
a Data for two patients are not available
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measured beginning with Part A cohort 3 onward (18). The
use of this plasma assay in conjunction with the radio-
graphic assessment of the large vessels using contrast CT
scans represented an additional risk evaluation in patients
treated with LY2157299. A sustained reduction in cystatin
C levels that may have indicated the development of
aneurysms was not apparent for any patient, whether dosed
with monotherapy or in combination with lomustine
(Fig. 4).
Electrocardiogram
As part of the comprehensive cardiac safety evaluation of
LY2157299, electrophysiological changes were monitored
by local and central assessments by cardiologists. Based on
the preclinical studies (in vitro and animal in vivo studies),
LY2157299 was not associated with QTc prolongation, but
this additional monitoring was performed to complement
the other cardiac monitoring examinations. We obtained
Fig. 4 Serum cardiac markers and changes over time for brain
natriuretic factor (BNP), cystatin C and high-sensitive C-reactive
protein (hs-CRP). Horizontal lines reflect the norm values. Blue lines
represent patients who received LY2157299 as monotherapy and red
for patients who were treated with the combination of LY2157299
and lomustine
Table 3 Summary of number of patients with TEAEs and CTCAE severity grade by study part and study treatment relatedness
Study part TEAEs Related to study treatments
C1 TEAE
n (%)
C1 Grade 3/4
n (%)
C1 TEAE
n (%)
C1 Grade 3/4
n (%)
Part A (N = 39) 37 (95) 24 (62) 10 (26) 3 (8)
Part B (N = 26) 26 (100) 22 (85) 15 (58) 8 (31)
Part C (N = 14) 14 (100) 7 (50) 3 (21) 2 (14)
Total (N = 79) 77 (97) 53 (67) 28 (35) 13 (16)
Study treatment relatedness in Part B is to either LY2157299, lomustine or both
CTCAE common terminology criteria for adverse events, TEAEs treatment-emergent adverse events
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complete ECG readings in 60 patients (60/79; 76 %) and
normal ECG readings were observed in 50 % (30/60) at
baseline. There was a change to abnormal at least once
during treatment in approximately one-third of all patients
(Table 4). For patients who continued on treatment, there
was no general increase in QTcF or PR rate (Fig. 5). A
change of[30 ms in QTcF (Fridericia) was observed in
10/44 patients (22.7 %) during monotherapy treatment
(Table 4). There was no patient who had a QTcF prolon-
gation of more than 60 ms or had an excursion over
500 ms. LY2157299 plasma concentration and ECG mea-
surements were not time-matched; however, 16 % of
observations were within 10 min, 33 % were within
30 min, 54 % within 1 h and 99 % within 2 h of each
other. We used information from a predictive population
PK model [14], simulating the individual patient plasma
concentration at the exact time of ECG measurement to
investigate whether there was a potential for LY2157299 to
be associated with QTcF prolongation. Based on this
model, we were reassured that the concentrations in
humans were not likely to be associated with any QTcF
prolongation (data not shown).
Computer Tomography Scan of the Upper Thorax
Using CT imaging, we did not find any evidence of
changes to the ascending aorta or aortic arch.
Blood Pressure
Blood pressure was evaluated after the first administration
during Cycle 1 in Parts A and B of the study. This
assessment was designed to determine whether there was
an immediate, short-term effect of LY2157299 on blood
pressure. Short-term evaluation for Part C was not carried
out. During this short-term evaluation (during the first
hours post-LY2157299 administration), no changes in
systolic and diastolic blood pressure were observed
(Fig. 6). LY2157299 had no influence on blood pressure as
described for anti-angiogenic compounds.
Echocardiography/Doppler
The transthoracic 2D echocardiography/color Spectral
Doppler examination assessed overall cardiac structure and
Table 4 Summary of changes from baseline in overall electrocardiogram assessments and in QTc (Fridericia)
Monotherapy
Baseline
Missing or normal ECG Abnormal ECG
22/42 (52 %) 20/42 (48 %)
Change from baseline
Normal ECG to abnormal Abnormal to normal
11/52 (26 %) 1/42 (2 %)
Combination
Baseline
Normal ECG Abnormal ECG
8/18 (44 %) 10/18 (56 %)
Change from baseline
Normal ECG to abnormal Abnormal to normal
6/18 (33 %) 0/18 (0 %)
Increase QTcF interval Monotherapy
n/N (%)
Combination
n/N (%)
0 and 30 ms 30/44 (68) 16/19 (84)
30 and 60 ms 10/44 (23) 3/19 (16)
[60 ms 0/44 (0) 0/19 (0)
Only includes patients who have both baseline and post-dose electrocardiogram measurements
ECG electrocardiogram
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function, and potential toxicity risks related to damage to the
heart valves, myocardium, or pericardium. The left ven-
tricular function was not changed, including in patients who
received treatments longer than six cycles (Fig. 7). In 15
patients, there was a change from baseline that was consid-
ered per protocol and central review as potentially patho-
logical, because the valve function suggested a change from
a lower risk to amoderate risk. Another patient experienced a
change by two severity grades (absent tomild) (Table 5). All
these changeswere not consideredmedically significant, and
the patient who experienced a change of two severity levels
had no other signs of cardiac injury, including plasmaBNPor
troponin I levels. In this patient, a pulmonary embolism was
detected, which may contribute to the changes observed in
the echocardiography/Doppler imaging.
Discussion
We report on a prospective and comprehensive cardiac
monitoring strategy to assess potential cardiac toxicities for
the TGF-b inhibitor LY2157299. Because of the toxicities
observed in animals with TGF-b RI inhibitors, we estab-
lished a cardiac monitoring approach that would detect
early signs of cardiac dysfunction. The cardiac toxicity in
animals was focused on two major toxicities: (a) valvular
changes with localized inflammatory infiltrates and
(b) aneurysms observed in dogs and rats treated with
LY2157299 continuously for 6 months. In oncology, car-
diac toxicity assessments have become increasingly
important as preventative strategies are needed to reduce
chemotherapy-related cardiac toxicities [20]. Despite this
need to assess cardiac safety comprehensively, clinical
trials in cancer patients seem to continue to underestimate
the risk of cardiac toxicity [21]. This discrepancy may have
two main reasons: (1) Toxicities in animal toxicology
studies are viewed as not consistently predictive for
humans; (2) cardiac toxicities are seen only after several
years post-treatment as observed in survivors of pediatric
cancer [22]. With treatments containing anthracyclines and
bevacizumab, cardiac toxicities are observed in a contin-
uum of time, some occur during the treatment and other
Fig. 5 Select electrocardiogram (ECG) parameters. Heart rate as assessed at time of ECG readings. PR rate, QT, and QTcF. Blue lines represent
patients who received LY2157299 as monotherapy and red for patients who were treated with the combination of LY2157299 and lomustine
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patients exhibit the toxicity after treatment [23, 24]. In
contrast to such variable or delayed toxicities, LY2157299
or similar TGF-b RI small molecular inhibitors are asso-
ciated with an immediate cardiac toxicity in animals.
Hence, the implementation of comprehensive cardiac tox-
icity monitoring during the FHD study was imperative.
While we expected that the anticipated therapeutic window
would not be associated with cardiac toxicity, we needed to
Fig. 6 Blood pressure changes over time after the first dose of
LY2157299 using cuff-measurements (horizontal lines represent
normal ranges). Systolic and diastolic blood pressure values over
time during the long-term treatment for patients receiving
LY2157299 monotherapy [systolic blood pressure (c); diastolic blood
pressure (d)] and combination of LY2157299 and lomustine [systolic
blood pressure (a); diastolic blood pressure (b)]
Fig. 7 Left ventricular (LV) ejection fraction for monotherapy LY2157299 and combination of LY2157299 and lomustine (red line represents
the normal value and open circles are patients outside of the confidence intervals)
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Table 5 Listing of patients whose aortic, mitral, and tricuspid valve assessment by deterioration of at least 1 category of severity
Patient Visit Valvular assessment (aortic = A, mitral = M, tricuspid = T) Systolic blood
pressure (mmHg)
Absent Trace Mild
R4 Baseline A, M T 140
1 M 141
R30 Baseline A, M T 104
1–14 M T 104–138
14 M T 138
R5 Baseline A, M T 135
1–2 M 110–120
2 M 110
R6 Baseline A, M, T 130
1–2 T 140–150
2 T 140
R7 Baseline A, M T 120
1–2 M 110–140
2 M 110
R12 Baseline A, T M 140
1–2 M T 125–130
2 M T 130
R20 Baseline A, M T 136
1–2 M 129–134
2 M 129
R21 Baseline A, M T 126
1–31 M 105–135
31 M 135
R26 Baseline A, M, T 134
1–2 M 124–130
2 M 130
R41 Baseline A, M, T 120
1–2 M, T 130
2 M T 130
R42 Baseline A M, T 120
1–8 M 117–125
8 M 120
R53 Baseline A T M 176
1 T 158
R54 Baseline A M, T 106
1–10 T 84–105
10 T 93
R62 Baseline A, M, T 110
1–12 M, T 81–110
12 M, T 81
R65 Baseline A T M 117
1–4 T 120–130
4 T 120
Italics decreased by 1 grade; bold increased by 1 grade; bold italics increased by 2 grades
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collect sufficient data to prove that the chosen therapeutic
window was safe. We combined imaging assessments such
as CT scans every 6 months for aneurysm evaluation, and
echocardiography/Doppler every 2 months for valve for-
mation, with plasma/serum cardiac risk markers.
Echocardiography/color Spectral Doppler was used to
monitor possible structural and functional changes of the
heart valves [17]. Because TGF-b signaling and serotonin
up-regulation in valvular toxicities have been associated,
we used echocardiography/color and Spectral Doppler
monitoring because it had been useful in identifying the
serotonin-induced valve changes [25], in addition to
monitoring potential toxicity to myocardial ventricular
function. Alternatively, we considered the use of MRI [26],
but decided against it because of the patient population and
the need to compare results from various study sites.
However, echocardiography/Doppler requires that patients
are appropriately positioned and cooperative with the
examination. In patients with end-of-life conditions, this
may sometimes cause compliance issues; hence, the quality
of the images can be sub-optimal. Images were generally of
good quality, judged both by local review and by the
central lab over read. Dual reading is advantageous in a
multi-site study, by providing a local review for immediate
patient safety, and a central review for consistent quanti-
tation. A disadvantage for the central reviewer is the lack
of important clinical information that generally helps in
assessing the significance of abnormalities. For example,
approximately 70 % of the patients had minimal or small
pericardial effusions per central review, deemed medically
insignificant by the local cardiologist.
Biomarkers such as BNP and troponin I allowed more
frequent monitoring than echocardiography/Doppler. They
are used during chemotherapy to detect potential cardiac
toxicities [27]. Hence, there is a good understanding on
their levels in cancer patients. We observed that none of the
patients had an increase of troponin I above 1.0 lg/L.
There were some patients who had a slight elevation of
about 0.6 lg/L at the start of the trial and also occasionally
during the treatment. However, this either did not increase
or returned to norm values. This observation is consistent
with other tumor types [28] and the slight increases in
troponin I are seen in inflammatory conditions [29]. Recent
guidelines provide recommendations on the interpretation
of troponin elevations in different diseases [30]. The BNP
values after age adjustment were generally within the norm
values prior to the treatment and in most patients remained
unchanged or even decreased. Serial BNP and troponin I
levels supported the echocardiography/Doppler findings as
previously described in patients with heart failure [31]. The
use of hs-CRP was intended to detect inflammatory con-
ditions that may have been induced by blocking the TGF-b
secretion. In toxicology studies of the rat with LY2157299,
aneurysms were associated with inflammatory cell infil-
trates. Hence, the hs-CRP was used as a possible early
detection signal [32]. Except for occasional increases in
some patients that were associated with infection, the hs-
CRP did not increase over time. The regular assessment of
cystatin C was implemented as a potential marker for early
detection in aneurysms because its reduction over time is
associated with abdominal aneurysms [18]. The cystatin C
levels were unchanged throughout the treatment with a few
reductions in patients treated with LY2157299. In some
patients with low pre-treatment levels, there were occa-
sional reductions. However, in such patients or all other
patients, the CT scans did not detect aneurysms in the
thoracic aorta.
Although LY2157299 treatment was not associated with
changes in the HERG-assay or in ECG evaluations in
animals, we used ECG as an additional measure for cardiac
safety. In general, about half of the patients had an
abnormal ECG at baseline that did not change during
treatment. This proportion of abnormal baseline ECGs is
expected in a sample of adult patients in a clinical trial. In
about one-third of the patients, the ECG readings changed
from normal to abnormal. The frequencies of patients with
a QTc increase of more than 30 ms were about 20 %; no
patient had a prolongation of more than 60 ms. After
excluding influence factors such as co-medications with
known QTc prolongation and considering the comorbidi-
ties of patients, there was no indication that LY2157299
induced QTc prolongation.
During treatment with LY2157299, the cardiac health of
the glioma patients was unremarkable; LVEF remained
unchanged and the blood pressure remained stable. The
cardiac medication remained unaltered and patients did not
require additional heart medication during the trial. This is
also reflected in the serious adverse event/AE reports; no
cardiac toxicities were reported. The case of one ischemic
event happened after the patient had undergone a re-
resection of his tumor and thus was attributed to the sur-
gery. Pulmonary embolism and dyspnea were considered to
be associated with the disease as previously reported [33].
As part of the cardiovascular monitoring, all patients
had to report the intake of LY2157299 in relationship to
food. Because of the stringent administration requirements,
patients administered LY2157299 early in the morning
(8:00 ± 1 h) and early evening (18:00 ± 1 h). Because of
this stringent administration schedule, diurnal fluctuations
in cardiac monitoring were assessed and not observed.
An additional benefit of the comprehensive cardiovas-
cular evaluation in this study is to confirm the stability of
cardiac function, biomarkers and ECG parameters in
sample of very ill cancer patients. Future studies of other
cancer therapies can benchmark against these findings,
allowing development teams to better determine whether
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an observed deterioration of cardiac function is due to drug
or to the natural history of a late stage cancer.
Based on the lack of any medically significant cardiac
events during the administration of LY2157299 either as a
short-term or long-term treatment (including in patients
treated over 3 years), either the therapeutic window was
accurately predicted by the PK/PD model or the preclinical
data in rats and dogs were not as predictive. Recently,
studies were published that suggest TGF-b is regulated
differently in inbred rats, some of which are used in the
preclinical assessment of toxicity risk [34]. Furthermore, if
shear/stress is a key inducer for TGF-b signaling [35], a
block of this pathway may be resulting in more evident
toxicity in species where the intravascular pressure is
higher than in humans.
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